| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
General Counsel & Corp. Sec'y
1 company
Mike Ouimette last filed a Form 4 in January 2025, as General Counsel & Corp. Sec'y at PLRX. Mike Ouimette's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Mike Ouimette's trades have earned a strong insider score of 81/100 across 11 rated trades. Over a 12-month horizon, all 11 of those trades were profitable, with an average 12-month return of +46.3%.
At the last filing, the largest reported position was 105,544 shares of PLRX. The PLRX filings lean toward selling, a net 89,284 shares.
Mike Ouimette has 18 Form 4 filings on record from October 2020 to January 2025, all as General Counsel & Corp. Sec'y at Pliant Therapeutics (PLRX), 2020–2025.
The 27 reported transactions were 12 open-market sales, 7 stock awards, 6 option or other derivative awards and 2 option exercises.
Counted by filing, the open-market trades come to no purchases and 9 sales worth about $1.8M.
The largest open-market sale was 20,000 shares of PLRX at an average $34.19 on January 23, 2023, about $684K. Twelve months later PLRX was down 42%.
All 6 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
Shares as reported in the last Form 4 for each company; the most recent is from January 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 22, 2025 | PLRX Pliant Therapeutics, Inc. | General Counsel & Corp. Sec'y | Sell10b5-1 | 23,500 | $11.11 | $261,101.08 | -25.0% | -86.3% | -88.1% | |
| Jul 10, 2024 | PLRX Pliant Therapeutics, Inc. | General Counsel & Corp. Sec'y | Sell10b5-1 | 7,656 | $11.56 | $88,503.36 | -7.5% | +1.4% | -87.4% | |
| Jan 17, 2024 | PLRX Pliant Therapeutics, Inc. | General Counsel & Corp. Sec'y | Sell10b5-1 | 5,197 | $17.23 | $89,544.31 | -8.6% | -25.7% | -35.0% | |
| Jul 20, 2023 | PLRX Pliant Therapeutics, Inc. | General Counsel & Corp. Sec'y | Sell10b5-1 | 4,755 | $17.55 | $83,450.25 | -7.3% | -22.6% | -29.4% | |
| Jul 17, 2023 | PLRX Pliant Therapeutics, Inc. | General Counsel & Corp. Sec'y | Sell10b5-1 | 12,778 | $18.01 | $230,120.28 | -16.4% | -13.7% | -24.3% | |
| Apr 3, 2023 | PLRX Pliant Therapeutics, Inc. | General Counsel & Corp. Sec'y | Sell10b5-1 | 7,751 | $26.62 | $206,329.08 | -13.2% | -32.0% | -44.6% | |
| Jan 23, 2023 | PLRX Pliant Therapeutics, Inc. | General Counsel & Corp. Sec'y | Sale+OE | 20,000 | $34.19 | $683,878.00 | -77.1% | +0.9% | -42.4% | |
| Dec 22, 2022 | PLRX Pliant Therapeutics, Inc. | General Counsel & Corp. Sec'y | Sell | 2,928 | $19.38 | $56,730.88 | -33.0% | +34.2% | -11.2% | |
| Dec 20, 2022 | PLRX Pliant Therapeutics, Inc. | General Counsel & Corp. Sec'y | Sell | 4,719 | $19.10 | $90,144.23 | -34.7% | +45.1% | -14.4% |